Shanghai Municipal Science and Technology Commission   Report issue

Government Phase 2 Phase 3 Phase 4
Founded: Shanghai China (2008)

Organization Overview

First Clinical Trial
2008
NCT01124253
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Shanghai Municipal Science and Technology Commission

Active Ingredients

Drugs in Phase 4 Trials (6)

citalopram (celexa) (1 trial)

fluoxetine (prozac) (1 trial)

fluvoxamine (luvox) (1 trial)

naoxintong (1 trial)

paroxetine (paxil) (1 trial)

sertraline (zoloft) (1 trial)

Drugs in Phase 3 Trials (1)

endostatin (endostar) (1 trial)

Drugs in Phase 2 Trials (2)

berberine (1 trial)

pioglitazone (actos) (1 trial)

Drugs in Other Trials (1)

conbercept (Lumitin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anxiety Disorders (Phase 4)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Cerebral Infarction (Phase 4)

Compulsive Personality Disorder (Phase 4)

Disease (Phase 4)

Fatty Liver (Phase 2)

Ischemia (Phase 4)

Liver Diseases (Phase 2)

Lung Neoplasms (Phase 3)

Mental Disorders (Phase 4)

Non-alcoholic Fatty Liver Disease (Phase 2)

Obsessive-Compulsive Disorder (Phase 4)

Stroke (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 10